Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
730 Stockton Drive
Exton, PA 19341
United States of America
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs. We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 inhibitor deficiency. In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.
ViroPharma (Cinryze brand of C1 Inhibitor) a plasma derived and nano filtered C1 inhibitor concentrate product that is produced from US source plasma at Sanquin's plant in Amsterdam, The Netherlands.
Cinryze is was approved in October 2008 in the US for preventive treatment of hereditary angioedema in adults and adolescents. In June 2011 Cinryze also was approved throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. Cinryze is approved for self administration in adults and adolescents for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.
In countries where Cinryze is currently not approved or available, ViroPharma offers a Named Patient Program (NPP).